Current issue
Archive
Manuscripts accepted
About the Journal
Editorial office
Editorial board
Section Editors
Abstracting and indexing
Subscription
Contact
Ethical standards and procedures
Most read articles
Instructions for authors
Article Processing Charge (APC)
Regulations of paying article processing charge (APC)
HEMATOLOGY / RESEARCH LETTER
Which myelofibrosis patients benefit from treatment with ruxolitinib? A single-center experience
1
4th Department of Internal Medicine – Haematology, University Hospital and Charles University, Hradec Kralove, Czech Republic
Submission date: 2025-06-28
Final revision date: 2025-07-23
Acceptance date: 2025-08-05
Online publication date: 2025-08-27
Corresponding author
Petra Belohlavkova
4th Department of Internal Medicine – Haematology University Hospital and Charles University, Hradec Kralove, Czech Republic
4th Department of Internal Medicine – Haematology University Hospital and Charles University, Hradec Kralove, Czech Republic
Arch Med Sci 2025;21(4):1658-1662
TOPICS
REFERENCES (15)
1.
Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010; 115: 1703-8.
2.
Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011; 29: 392-7.
3.
Tefferi A, Guglielmelli P, Lasho TL, et al. MIPSS70+ version 2.0: mutation and karyotype-enhanced international prognostic scoring system for primary myelofibrosis. J Clin Oncol 2018; 36: 1769-70.
4.
Tefferi A, Guglielmelli P, Nicolosi M, et al. GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. Leukemia 2018; 32: 1631-42.
5.
Harrison CN, Vannucchi AM, Kiladjian JJ, et al. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia 2016; 30: 1701-7.
6.
Verstovsek S, Mesa RA, Gotlib J, et al. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. J Hematol Oncol 2017; 10: 55.
7.
Emanuel RM, Dueck A, Geyer H, et al. The Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS): prospective international assessment of an abbreviated symptom burden scoring system among 1408 MPN patients. J Clin Oncol 2012; 30: 4098-103.
8.
Oken M, Creech R, Tormey D, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-55.
9.
Coltro G, Sant’Antonio E, Palumbo GA, et al. Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real-life setting: an Italian MYNERVA Project. Cancer Med 2023; 12: 8166-71.
10.
Al-Ali HK, Griesshammer M, Foltz L, et al. Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts. Br J Haematol 2020; 189: 888-903.
11.
Luo Q, Xiao Z, Peng L. Effects of ruxolitinib on infection in patients with myeloproliferative neoplasm: a meta-analysis. Hematology 2021; 26: 663-9.
12.
Landtblom AR, Bower H, Andersson TM, et al. Second malignancies in patients with myeloproliferative neoplasms: a population-based cohort study of 9379 patients. Leukemia 2018; 32: 2203-10.
13.
Passamonti F, Heidel FH, Parikh RC, et al. Real-world clinical outcomes of patients with myelofibrosis treated with ruxolitinib: a medical record review. Future Oncol 2022; 18: 2217-31.
14.
Maffioli M, Mora B, Ball S, et al. A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis. Blood Adv 2022; 6: 1855-64.
15.
Bose P. Management of patients with early myelofibrosis: a discussion of best practices. Curr Hematol Malig Rep 2024; 19: 111-9.
| eISSN: | 1896-9151 |
| ISSN: | 1734-1922 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
